With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012
This article was originally published in The Pink Sheet Daily
Merck’s delay of filing an NDA for its osteoporosis drug odanacatib surprised analysts, but Merck remained mum on its reasoning in a year-end earnings call on Feb. 1.
You may also be interested in...
At a May 6 investor day, Merck’s R&D head Roger Perlmutter revealed the safety issues that have been delaying the company’s late-stage osteoporosis drug and tried to renew confidence in the treatment.
In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.